Human Fc gamma RIIIA / CD16a (V176) Protein, HSA,His Tag (MALS & BLI verified)

Customer Reviews
Cat. No. / Size
Price
Qty
CDA-H52S1-50ug
$225.00
CDA-H52S1-100ug
$290.00
CDA-H52S1-1mg
$2040.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    FCGR3A, CD16A, FCG3, FCGR3, IGFR3

  • Source

    Human CD16a (V176), HSA,His Tag (CDA-H52S1) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1 (F176V)).

    Predicted N-terminus: Gly 17

    Request for sequence
  • Molecular Characterization

    Fc gamma RIIIA / CD16a Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a HSA tag at the C-terminus, followed by a polyhistidine tag.

    The protein has a calculated MW of 90.6 kDa. The protein migrates as 90-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    Fc gamma RIIIA / CD16a SDS-PAGE

    Human CD16a (V176), HSA,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    Fc gamma RIIIA / CD16a SEC-MALS

    The purity of Human CD16a (V176), HSA,His Tag (Cat. No. CDA-H52S1) is more than 95% and the molecular weight of this protein is around 100-120 kDa verified by SEC-MALS.

    Report
  • Bioactivity-BLI

     Fc gamma RIIIA / CD16a BLI

    Loaded Rituximab on Protein A Biosensor, can bind Human CD16a (V176), HSA,His Tag (Cat. No. CDA-H52S1) with an affinity constant of 1.5 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

    Protocol
  •  Fc gamma RIIIA / CD16a BLI

    Loaded Rituximab on FAB2G Biosensor, can bind Human CD16a (V176), HSA,His Tag (Cat. No. CDA-H52S1) with an affinity constant of 0.369 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  Fc gamma RIIIA / CD16a BLI

    Loaded Human CD16a (V176), HSA,His Tag (Cat. No. CDA-H52S1) on HIS1K Biosensor, can bind Rituximab with an affinity constant of 0.387 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Recent Advances

 
Drug Development Progress
  • English Name:

    Low affinity immunoglobulin gamma Fc region receptor III-A

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    14 Details

  • Highest Development Stage:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background